Product image of Izilox (Moxifloxacin) supplied by GNH India

Izilox

Active Ingredient:
Moxifloxacin
Origin:
EU

Izilox (Moxifloxacin)

Moxifloxacin, the active ingredient in Izilox, is a Fluoroquinolone presented as an injection solution for intravenous use. It treats serious bacterial infections such as community‑acquired pneumonia, acute bacterial sinusitis, skin and soft tissue infections, and complicated intra‑abdominal infections in adult patients.

GNH India supplies Izilox as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals worldwide.

Manufacturer / TM Owner

Bayer Healthcare

1
Pack/s
This product is added to your enquiry list

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

A minimum order value applies. Our team will confirm the exact amount or quantity after reviewing your requirements.

Indications & Clinical Uses

Moxifloxacin is a fluoroquinolone antibacterial indicated for several serious bacterial infections.

  • Community‑acquired bacterial pneumonia: provides rapid bacterial eradication and clinical improvement.
  • Acute bacterial sinusitis: resolves sinus infection symptoms and clears pathogenic organisms.
  • Skin and soft tissue infections: treats complicated cellulitis and wound infections caused by susceptible bacteria.
  • Complicated intra‑abdominal infections: targets mixed aerobic and anaerobic pathogens to control intra‑abdominal sepsis.

How It Works

  • Moxifloxacin exerts bactericidal activity by binding to bacterial DNA gyrase and topoisomerase IV, enzymes essential for DNA supercoiling and replication. Inhibition of these targets prevents DNA synthesis and transcription, leading to cell death in susceptible Gram‑positive and Gram‑negative bacteria.

Side Effects

Adverse reactions may occur with any antibacterial therapy.

Common Side Effects

  • Nausea: mild to moderate gastrointestinal upset.
  • Diarrhea: loose stools, occasionally watery.
  • Headache: transient cranial discomfort.
  • Dizziness: sensation of light‑headedness.
  • Rash: mild skin erythema or pruritus.
  • Elevated liver enzymes: transient increase in hepatic transaminases.

Serious or Rare Side Effects

  • Tendon rupture: especially Achilles tendon, may occur without warning.
  • QT interval prolongation: risk of cardiac arrhythmias.
  • Clostridioides difficile infection: severe colitis after antibiotic exposure.
  • Severe allergic reactions: anaphylaxis, angioedema.
  • Hepatic failure: rare but potentially life‑threatening liver injury.
  • Anaphylactic shock: immediate hypersensitivity requiring emergency care.

Precautions & Warnings

Use of Izilox requires careful clinical assessment and monitoring.

  • Renal impairment: monitor renal function and adjust therapy as needed.
  • Hepatic impairment: use with caution; observe liver function tests.
  • Concomitant QT‑prolonging drugs: assess cardiac risk and monitor ECG.
  • History of tendon disorders: avoid use due to increased rupture risk.
  • Pregnancy and lactation: safety not established; prescribe only if benefits outweigh risks.
  • Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Avoid Interactions

Moxifloxacin may interact with several drug classes, requiring vigilance.

Major Interactions (Avoid)

  • Other fluoroquinolones: additive toxicity.
  • Antacids containing magnesium or aluminum: reduce absorption.
  • Cyclosporine: increased serum levels and nephrotoxicity.
  • Warfarin: enhanced anticoagulant effect, risk of bleeding.
  • Theophylline: elevated plasma concentrations, risk of toxicity.

Moderate Interactions (Monitor Closely)

  • Non‑steroidal anti‑inflammatory drugs (NSAIDs): heightened CNS stimulation.
  • Diuretics (especially thiazides): potential hypoglycemia.
  • Corticosteroids: increased risk of tendon rupture.

Frequently Asked Questions

Izilox is a sterile intravenous formulation of moxifloxacin indicated for the treatment of serious bacterial infections, including community‑acquired pneumonia, acute bacterial sinusitis, skin and soft tissue infections, and complicated intra‑abdominal infections in adult patients.

Moxifloxacin inhibits bacterial DNA gyrase and topoisomerase IV, enzymes required for DNA replication and transcription. By blocking these targets, it prevents bacterial DNA synthesis, leading to rapid bactericidal activity against a broad spectrum of Gram‑positive and Gram‑negative organisms.

The dosage and duration of Izilox are determined by the prescribing clinician based on the infection type, severity, patient weight, renal and hepatic function, and local antimicrobial guidelines. No fixed regimen is provided here.

Safety of moxifloxacin during pregnancy and lactation has not been established. It should be used only when the potential benefit justifies the potential risk to the fetus or infant, and after a thorough risk‑benefit assessment by the healthcare provider.

To order Izilox, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain if needed) and required import documentation.

Izilox (moxifloxacin) offers a broader spectrum against both Gram‑positive and Gram‑negative bacteria compared with older fluoroquinolones such as levofloxacin, and it provides once‑daily dosing in many regimens. However, safety considerations like tendon risk and QT prolongation are similar across the class, so choice depends on susceptibility patterns and patient risk factors.

Izilox must be stored refrigerated between 2 °C and 8 °C, protected from light, and must not be frozen or shaken. Prior to use, allow the product to reach room temperature if required, and follow aseptic techniques for reconstitution and intravenous administration.

Izilox is given by intravenous infusion. The sterile vial is reconstituted with the appropriate diluent, then administered over the prescribed infusion time, typically as a slow push or short infusion, under the supervision of qualified healthcare personnel.

Serious adverse events include tendon rupture (especially Achilles), QT interval prolongation leading to arrhythmias, Clostridioides difficile‑associated colitis, severe hypersensitivity reactions such as anaphylaxis, and rare cases of hepatic failure. Prompt medical attention is required if any of these occur.

Izilox is contraindicated in patients with a known hypersensitivity to moxifloxacin or other fluoroquinolones, those with a history of tendon disorders related to fluoroquinolone use, pregnant or nursing women unless absolutely necessary, and children or adolescents for whom safety has not been established.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated:

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.

Related Products

Other formulations containing Moxifloxacin

A

A
A

A
A

A
A

A

Browse all products →

Ordering Process

Simple, Secure, and Seamless

Learn how our streamlined ordering process guarantees fast, compliant, and reliable access to essential medicines worldwide.

Quote request form

01

Submit Quote Request Form

Tell us what medications you need by filling out our simple form and uploading a valid document.

Price estimate review

02

We Review & Send Estimate

Our licensed pharmacists will verify your details and provide you with a detailed cost estimate.

Secure payment

03

Confirm & Make Payment

Discuss any queries, approve the estimate, and complete your payment.

Worldwide delivery

04

Get Delivered

Your medicines, safely packed and delivered to your door or nearest airport — hassle-free.

Regulatory recognitions

Quality You Can Trust

Our internationally recognized certifications underscore our commitment to safety, quality, and excellence.

SGS GSDP Certification

GSDP Compliant from SGS

URS ISO 9001

URS ISO 9001 Certification

FDA Maharashtra

Licensed by FDA Maharashtra

IEC License DGFT

IEC License issued by DGFT